Current as of October 13, 2025

Regular Abstracts to be presented

Poster Session A (To be presented October 23, 2025, 12:30-4pm ET)

A001 **Prevalence of Common HLA Class I Alleles in a Spanish Oncology Cohort Prescreened for Early-Phase Trials: Implications for Broadening Access to HLA-Restricted Therapies**. Paula Villalba-Cuesta. Fundación Jiménez Díaz University Hospital, Madrid, Spain.

A002 **Safety and efficacy of imetelstat in myeloid malignancies: A systematic review**. Ammar Altaweel. Jordan University of Science and Technology, Irbid, MS, Jordan.

A003 **Baseline levels of HIF2 target proteins and response to the HIF2α inhibitor NKT2152 in patients with metastatic clear cell renal cell carcinoma**. Gabriel de Oliveira. Brigham and Women's Hospital, Boston, MA, United States.

A004 **Comprehensive cytokine and chemokine evaluation in plasma samples of primary, non-metastatic high grade serous ovarian cancer patients to estimate outcome and platinum resistance.**. Yipeng Wang. LuminoDx, San Diego, CA, United States.

A005 **MGMT as a pan-cancer biomarker in temozolomide preclinical studies using models from the NCI PDMR**. Li Chen. Frederick National Laboratory for Cancer Reserach, Frederick, MD, United States.

A006 **Biomarker analyses of WEE1 inhibition in patients with refractory CCNE1 amplified solid tumors**. Siqing Fu. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A007 **Is liquid biopsy a reliable surrogate for MSI testing? A concordance study using matched tissue and ctDNA-based NGS**. Julieta Rodriguez. Gustave Roussy, Villejuif, France.

A008 **TIGIT, CD155 (PVR), and Trop-2 expression characterization across histology and PD-L1 subgroups in non−small cell lung cancer (NSCLC)**. Marianna Zavodovskaya. Gilead Sciences, Inc, Foster City, CA, United States.

A009 **Clinical value of ctDNA tumor fraction (TF) and evolving genomic landscape across lines of therapy (LOTs) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)**. Candice Francheska Tambaoan. Foundation Medicine, Inc., Boston, MA, United States.

A010 **Synergistic ovarian cancer killing by combination of PARG and USP1 inhibitors: Role of single stranded DNA gaps as a predictive biomarker**. Ramya Ravindranathan. Dana Farber Cancer Institute/ Harvard Medical School, Boston, MA, United States.

A011 **Rationale for the use of Azenosertib in Early Line Treatment of Cyclin E1-Positive High-Grade Serous Ovarian Cancer**. Mona Abed. Zentalis Pharmaceuticals, San Diego, CA, United States.

A012 **Comparative analysis of circulating variant allele fractions in healthy individuals and patients with solid tumors using an ultra-sensitive liquid biopsy assayMUTE-Seq**. Jungmin Kim. GeneCker, Seoul, United States.

A013 **Clinical Value of Tumor Mutational Burden (TMB) for Neoadjuvant and Adjuvant Immune Checkpoint Inhibitor (ICI) in Early-Stage (I-III) Non-Small Cell Lung Cancer (NSCLC)**. Amaya Gasco. Foundation Medicine, Boston, MA, United States.

A014 **Comprehensive genomic and clinicopathologic characterization of ESR1 mutations in Chinese breast cancer patients reveals distinct molecular features and metastasis-associated enrichment**. Kai Wang. OrigiMed, Shanghai, China.

A015 **Characterization of pharmacogenomic biomarkers in FDA oncology/hematology drug labelling: A descriptive regulatory review**. Alhanouf Alnafisah. Saudi FDA, Riyadh, Saudi Arabia.

A016 **cfDNA fragmentome predicts cancer treatment response similarly to mutant allele fraction**. Lorenzo Rinaldi. Delfi Diagnostics, Inc., Baltimore, MD, United States.

A017 **Retrospective descriptive analysis of FDA CDER and CBER drug development tool qualification programs in oncology and hematology: Implications for orphan drug submissions at the Saudi Food & Drug Authority**. Meshal Al-Kalabi. Saudi FDA, Riyadh, Saudi Arabia.

A018 **HLA-B44 Supertypes as Immune Biomarkers of Anti–PD-1/PD-L1 Response: Results from a Retrospective Analysis of a Spanish Precision Oncology Population**. Paula Villalba-Cuesta. Fundación Jiménez Diaz University Hospital, Madrid, Spain.

A019 **Single-cell analysis of tumor population diversity in synovial sarcoma**. Elena Kopantseva. Research Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation.

A020 **Real-world clinical implications of ctDNA-detected ERBB2 amplification across solid tumors in a precision oncology program.**. Veronique Debien. Institut Bergonie, Bordeaux, France.

A021 **Advanced Lung Adenocarcinoma in a Non-Smoker: Diagnostic Clarity Through Immunohistochemistry in the Face of Atypical Tumor Markers.**. Pavan kumar Macharla. Manipal hospitals, Vijayawada, India.

A022 **Multi-omics integration reveals TSPAN1 as a highly specific biomarker for early non-invasive diagnosis of ovarian cancer**. Yamin Zhao. The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

A023 **Erythropoietin (EPO) is a Pharmacodynamic Biomarker for Systemic HIF-2α Inhibition that Correlates with the Clinical Activity of Casdatifan**. Ben Weeder. Arcus Biosciences Inc, Hayward, CA, United States.

A024 **Tumor kinetic modeling of patients with gastric cancer reveals evolutionary factors associated with worse prognosis**. Arijit Chakravarty. Fractal Therapeutics, Inc., Lexington, MA, United States.

A025 **Inducing mitotic catastrophe in high replicative stress castration resistant prostate cancer through inhibition of WEE1**. Patricia Madel. University of Chicago, Chicago, IL, United States.

A026 **Discovery of potent and selective CDK2 molecule glue degraders for the treatment of HR+/HER2- breast cancer, and CCNE1 amplified tumors**. Nasrin Rastgoo. Plexium, San Diego, CA, United States.

A027 **First-in-class oral macrocyclic Cyclin D1-selective inhibitors demonstrate anti-tumor activity in Cyclin D1-dependent tumors**. Marie Evangelista. Circle Pharma, South San Francisco, CA, United States.

A028 **Novel Synthetic Lethality Opportunity for Ewing Sarcoma**. Shuhei Asada. Dana-Farber Cancer Institute, Boston, MA, United States.

A029 **Mechanistic insight into a germline KDM3C polymorphism associated with chemoradiotherapy outcomes in cancer**. Adria Hasan. Fox Chase Cancer Center, Philadelphia, PA, United States.

A030 **Discovery and preclinical characterization of novel macrocyclic KIF18A Inhibitors for treatment of chromosomally instable tumors**. Susanta Samajdar. Aurigene Oncology Ltd, Bengaluru, India.

A031 **DNA-PK reenforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy**. Timothy Branigan. Dana-Farber Cancer Institute, Boston, MA, United States.

A032 **PTEN protein and lipid phosphatase deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer**. Jie Hao. Dana-Farber Cancer Institute, Boston, MA, United States.

A033 **Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer**. Lokesh Akana. University of Arkansas for Medical Sciences, Little Rock, AR, United States.

A034 **USP1 inhibition disrupts DNA repair and potentiates the cytotoxic effects of DNA-damaging agents via persistent DNA damage in cancer cells**. Prashant Bhavar. VeGen Labs, Hyderabad, IN, India.

A035 **The nitroalkene (E)-8-nitrononadec-7-enoic acid (CP-8) is a potent and reversible inhibitor of HR-mediated DNA DSB repair**. Carola Neumann. University of Pittsburgh, Pittsburgh, PA, United States.

A036 **Synthetic RNA-guided combinatorial targeting of glioblastoma adaptive resistance: Dual suppression of PI3K-AKT and mesenchymal transition escape pathways**. Shivi Kumar. Mind Matters Foundation for Kids, Flower Mound, TX, United States.

A037 **Coordinated activity between AR-V7 and glucocorticoid receptor drives resistance to androgen receptor signaling inhibition**. Yuhan Zhang. The University of Chicago, Chicago, IL, United States.

A038 **Lomitapide enhances cytotoxic effects of temozolomide in chemo-resistant glioblastoma**. Alyona Ivanova. University of Toronto, Toronto, ON, Canada.

A039 **A whole genomic CRISPR-Cas9 screen identifies the LAT3 (SLC43A1) neutral amino acid transporter as a major determinant of oxaliplatin resistance in colorectal cancer cells**. Nisha Pawar. National Cancer Institute, Bethesda, MD, United States.

A040 **Resistance to trastuzumab deruxtecan acquired through multifaceted pathway alterations in preclinical models**. Emily Mason-Osann. AstraZeneca, Waltham, MA, United States.

A041 **Emergence of TOP1 mutations as a potential biomarker of resistance to topoisomerase-targeting regimens**. Tejaswini Reddy. Baylor College of Medicine, Houston, TX, United States.

A042 **Evolution of resistance in brain tumors: Effects of the blood brain barrier**. Madison Stoddard. Fractal Therapeutics, Lexington, MA, United States.

A043 **P-gp overexpression confers resistance to treatment with the antibody-drug conjugate mirvetuximab soravtansine**. Omotola Gbadegesin. National Cancer Institute, Bethesda, MD, United States.

A044 **Characterization of DS8201 (Enhertu) in a Clinically Pretreated NSCLC Patient-Derived Xenograft (PDX) Model**. Jinxi Wang. Crown Bioscience Inc., San Diego, United States.

A045 **Development of Patient-Derived Xenograft (PDX) Model with Acquired Resistance to KRASG12C Inhibitors**. Aaron Hua. Crown Bioscience Inc., San Diego, United States.

A046 **Real world adoption of off-label combination treatment to treat non-small cell lung cancer resistance**. Justin Battaglini. Boston Medical Center, Boston, MA, United States.

A047 **Bis-indole derived dual NR4A1/2 inverse agonists synergistically enhance temozolomide-induced cytotoxicity in glioblastoma cells through downregulation of drug-resistance genes**. Evan Farkas. Texas A&M University, College Station, TX, United States.

A048 **PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lung and colorectal cancer models**. Melissa Junttila. ORIC Pharmaceuticals, Inc., South San Francisco, CA, United States.

A049 **Impact of Actionable Genomic Alterations (AGA) on the Efficacy of Durvalumab in Patients with Locally Advanced NSCLC Treated with Concurrent Chemoradiotherapy.**. Jaime Rubio-Perez. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A050 **Effectiveness of PROTAC BET degraders ARV-825 and ARV-771 in combating chemoresistance in HNSCC**. Natalie Luffman. Virginia Commonwealth University, Richmond, VA, United States.

A051 **The long non-coding RNA PCA3 silencing sensitizes metastatic prostate cancer cells to docetaxel**. Ana Lemos. Center for Technological Development in Health, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

A052 **Enhancing potency through synergy: QP101, a novel HER2 targeting dual payload ADC shows potent preclinical activities**. Hwankyu Kang. Qurient Co. Ltd., Seongnam-si, Korea, Republic of.

A053 **Targeting Acquired Resistance to KRASG12DInhibitors: designing rationale synergistic treatments.**. Ines Pulido. University of Illinois Chicago, Chicago, United States.

A054 **Evaluation of HER3-targeting ADC patritumab deruxtecan in irinotecan-resistant colorectal cancer PDX models reveals resistance mechanisms and informs rational combination strategies**. Preeti Kanikarla. UT MD Anderson Cancer Center, HOUSTON, TX, United States.

A055 **Treatment and tumor heterogeneity – Effects of competition, variable response to treatment, and finite resources**. Madison Stoddard. Fractal Therapeutics, Lexington, MA, United States.

A056 **Therapeutic Evaluation of Brigimadlin and Anti-PD-1 in a PBMC-Co-culture Model of Patient-Derived Liposarcoma Organoids**. Kyuyoung Han. University of Ulsan, Asan Medical Center, Seoul, United States.

A057 **Hinge-targeting BRAF inhibitors with prolonged residence time for durable suppression of MAPK signaling**. Evangelia Matenoglou. Albert Einstein College of Medicine, Bronx, NY, United States.

A058 **Investigating metformin as a unique therapeutic for KRAS-mutant non-small cell lung cancer**. Margaret Larsen. LSUHSC, New Orleans, LA, United States.

A059 **Discovery of PSTA-2413, an oral pan-RAS inhibitor with wild type selectivity and potent in vitro and in vivo efficacy**. Chi-Chung Chan. Prospect Therapeutics, Shanghai, China.

A060 **Characterization of PSTA-5204, an oral KRAS G12D (ON) inhibitor with potent in vitro and in vivo efficacy**. Chi-Chung Chan. Prospect Therapeutics, Shanghai, China.

A061 **Identification and validation of integrin β1 as an in vivo-specific combination partner with MAPK pathway inhibitors in BRAF mutant colorectal cancer**. Hao Chen. Novartis Institutes for Biomedical Research, Cambridge, MA, United States.

A062 **RAS-GTP inhibition enhances antitumor efficacy of the RAF/MEK clamp avutometinib in NF1-associated Malignant Peripheral Nerve Sheath Tumors**. Arnab Sarkar. Oregon Health & Science University, PORTLAND, OR, United States.

A063 **BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models**. Carlos Stahlhut. BridgeBio Oncology Therapeutics, South San Francisco, CA, United States.

A064 **Chemical and structural mechanisms of RAS induced RAF:KSR dimerization**. Hiral Mistry. Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A065 **Small Molecule Modulation of Inactive-to-Active State Transitions of RAS:RAF-Family Complexes**. Yoonji Eum. MSKCC, New York, NY, United States.

A066 **SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors**. Seung Hyun Jung. Hanmi Pharmaceutical Co., Ltd., Hwaseong-si, Korea, Republic of.

A067 **Pan-RAS inhibition as a novel therapeutic strategy in RAS-driven rhabdomyosarcoma**. Patience Odeniyide. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

A068 **Preclinical investigation of orally bioavailable, potent pan-KRAS (ON/OFF) inhibitorJAB-23E73**. Yiwei Lin. Jacobio (US) Pharmaceuticals, Burlington, MA, United States.

A069 **RAS(ON) inhibitor in-pathway combinations maximize RAS pathway suppression, and drive deep and durable antitumor activity in KRAS mutant CRC models**. Xing Wei. Revolution Medicines, Inc., Redwood City, CA, United States.

A070 **Optimal efficacious dose prediction of a novel protein degrader ASP3082 selectively targeting KRAS G12D using quantitative systems pharmacology**. Pouye Sedighian. Astellas Pharma, Northbrook, IL, United States.

A071 **Non-clinical study of ASP4396, a novel KRAS G12D degrader, shows remarkable anti-tumor activity in KRAS G12D mutant cancer models**. Kanako Iguchi. Astellas Pharma Inc., Tsukuba, Japan.

A072 **KRASG12C mutationand metastatic colorectal cancer: Are we ready for neo-adjuvant? A case report.**. Sebastian Correa. Universidad Central del Caribe/UT MD Anderson Cancer Center, Bayamon, Puerto Rico.

A073 **Plixorafenib (PLX8394/FORE8394) treatment leads to sustained tumor regression in preclinical models of BRAF-mutated primary and brain metastatic melanoma**. Jessica Jang. Fore Biotherapeutics, Philadelphia, PA, United States.

A074 **DUSP4 loss: Anovel driver of colorectal cancer**. Kristen Needham. Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, VIC, Australia.

A075 **SHP2 inhibition is active in a RAS mutation-dependent manner and synergizes with RAS(ON) inhibition in models of fusion-negative rhabdomyosarcoma.**. Andrew Baker. Johns Hopkins School of Medicine, Baltimore, MD, United States.

A076 **VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors**. Silvia Coma. Verastem Oncology, Needham, MA, United States.

A077 **BGB3245-mediated RAF dimer disruption combined with MEK inhibition suppresses ERK reactivation in BRAF-mutant and ERK-dependent glioblastoma models**. Karisa Schreck. Johns Hopkins University, Baltimore, MD, United States.

A078 **Molecule Glue Profiling Unveils the Dynamics of KRAS-Induced Proximity**. Tiejun Bing. ICE Bioscience, Beijing, China.

A079 **Directed clonal evolution: Leveraging divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation**. Eunice Cho. Broad Institute, Cambridge, MA, United States.

A080 **Systematic PDX-based drug screening reveals genotype-specific vulnerabilities and therapeutic combinatorial opportunities in colorectal cancer**. Alexey Sorokin. UT MD Anderson Cancer Center, HOUSTON, TX, United States.

A081 **Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies**. Ida Aronchik. Revolution Medicines, Redwood City, CA, United States.

A082 **Dual targeting of BET and EP300 with XP-524 in pancreatic cancer lines resistant to KRAS inhibitors**. Arlinda Lee. XTRemisBio, Spartanburg, United States.

A083 **BRAF Inhibitors in BRAF V600E-Mutated Solid Tumors: A Real World Single Center Experience Post-Tumor-Agnostic FDA Approval**. Srinivas Govindan. Northwell Health Zuckerberg Cancer Institute, New Hyde Park, NY, United States.

A084 **Establishment of KRAS G12C Mutant Brain Metastasis Models for Pre-clinical Evaluation of KRAS G12C Targeted Anti-Cancer Therapy**. Takashi Willebrand. ChemPartner, San Francisco, CA, United States.

A085 **OBP-004, a novel small-molecule dual inhibitor of CDK9/13, reduces bone, brain, lung and lymph node metastases in vivo, with highest potency on bone metastases**. Tiina Kähkönen. OncoBone Therapeutics Ltd, London, United Kingdom.

A086 **Development and Preclinical Evaluation of a Potent and Selective MASTL Inhibitor for Breast Cancer Therapy**. Jae-Sung Kim. Korea Institute of Radiological and Medical Sciences, Seoul, United Kingdom.

A087 **Leveraging conformation selectivity of MAPK-targeting inhibitors for tumor-selective targeting of RAS-mutant cancers**. Poulikos Poulikakos. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

A088 **Revealing intrinsic ATPase activity in kinases: Implications for drug discovery using ADP-Glo assay**. Yusuke Kawase. Carna Biosciences, Inc., Kobe, Japan.

A089 **UnAcH416 (P2), a selective PRMT1 inhibitor, disrupts tumor cell growth and stress-response pathways**. Joseph Camps. University of North Florida, Jacksonville, FL, United States.

A090 **Vepugratinib (LY3866288), a potent highly isoform-selective FGFR3 inhibitor, enhances the activity of enfortumab vedotin (EV) in FGFR3-altered metastatic urothelial cancer (mUC) models**. Loredana Puca. Eli Lilly & Company, New York, NY, United States.

A092 **Discovery of ABK-CDK-1, a selective and brain penetrant CDK4/2 inhibitor to overcome resistance of CDK4/6 inhibitors in breast cancer**. Haiyan Ying. Abbisko Therapeutics, Shanghai, China.

A093 **VRN110755 Shows Promise with Improved Efficacy in EGFR mutation NSCLC: Highlighting CNS activity, Potency Against Resistant EGFR Mutations, and a Favorable Safety Profile**. Shuang Yin Zhang. Voronoi-USA, Boston, MA, United States.

A094 **Development of selective oxindole-based AMPK inhibitors and their evaluation as single agents and in combination with venetoclax in models of leukemia**. Juliet Strang. University of Colorado Anschutz, Aurora, CO, United States.

A095 **Tolerability and ocular adverse events of Datopotamab Deruxtecan in advanced cancers: A meta-analysis of phase III trials**. Daniel Jones. Department of Internal Medicine, Sunrise Health GME Consortium, Las Vegas, NV, Las Vegas, NV, United States.

A096 **Discovery of a covalent allosteric inhibitor targeting AKT1 E17K for the treatment of solid tumors**. Mengqi Zhong. Rezo Therapeutics, SAN FRANCISCO, CA, United States.

A097 **Global pharmacodynamic effects uncovered with AP3 phosphoproteomic profiling of novel WEE1/PKMYT1 inhibitor ACR-2316 reveals the critical importance of PLK1 for ACR-2316's superior preclinical activity and differentiated mechanism of action**. Subodh Kumar. Acrivon Therapeutics INC, Watertown, MA, United States.

A098 **Nuvisertib shows single-agent anti-tumor activity in multiple myeloma nonclinical models**. Zakir Khan. Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, United States.

A099 **NXP900, a novel YES1/SRC kinase inhibitor currently in clinical development, potently inhibits tumor growth in FAT1 mutated xenograft models**. Asier Unciti-Broceta. University of Edinburgh, Edinburgh, United Kingdom.

A100 **AXL Inhibitor AB801 Increases the Anti-Tumor Efficacy of KRAS Inhibition**. Susan Paprcka. Arcus Biosciences, Hayward, CA, United States.

A101 **Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specific T Cell Cytotoxicity**. Susan Paprcka. Arcus Biosciences, Hayward, CA, United States.

A102 **Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: Analysis from the phase 2 eNRGy Trial**. Alison Schram. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A103 **Identification and functional analysis of CLIC1(Chloride intracellular channel protein1)-binding peptide**. Aryeong Lee. Kyungpook National University, Daegu, Korea, Republic of.

A104 **ADoBind MC001: A first-in-class tetravalent chemoimmunotherapy ADC targeting folate receptor alpha for treatment of pancreatic cancer**. Seah Lim. Medicovestor, Inc, New York, NY, United States.

A105 **MC003: ADoTope, a first-in-class dual-payload bi-epitope combination chemoimmunotherapy antibody drug conjugate (ADC) targeting Folate Receptor Alpha**

(FRa) in platinum-resistant epithelial ovarian cancer.. Seah Lim. Medicovestor, Inc, New York, NY, United States.

A106 **Disrupting ribosome assembly to block protein translation: A novel ADC payload with strong antitumor activity in mono- and dual-payload formats**. Tara Arvedson. Hexagon Bio, Menlo Park, CA, United States.

A107 **Accelerating and Advancing Targeted Therapeutics: A One-Stop Service Platform for ADC and Next-Generation Conjugate Development**. Wei Li. MedChemExpress LLC, Monmouth Junction, NJ, United States.

A108 **Development of antibody drug conjugates targeting chondroitin sulfate proteoglycan 4 (CSPG4)**. Xiaoxuan Zhong. NYU Grossman School of Medicine, New York, NY, United States.

A109 **Treating pancreatic cancer with "armed" oncolytic adenoviruses and adoptive T-cell therapy**. Brett Roach. University of Minnesota, Twin Cities, Minneapolis, MN, United States.

A110 **Proteasome inhibitor (PI) ADC: A novel broad spectrum payload platform**. Won-Gyun Ahn. Qurient Co. Ltd., Seongnam-si, Korea, Republic of.

A111 **Preclinical evaluation of HC74, a novel topoisomerase I inhibitor payload for antibody–drug conjugates that overcomes multi-drug resistance**. Fenghua Zhang. Immunome, Research, Bothell, WA, United States.

A112 **Micvotabart pelidotin induces immunogenic cell death markers and activates tumor immune cells in pre-clinical studies**. Matthew Iovino. Pyxis Oncology, Boston, MA, United States.

A113 **Micvotabart pelidotin, a non-cellular targeting ADC, remodels the tumor microenvironment in tumors from participants in a phase 1 dose escalation study**. Sara Lewandowski. Pyxis Oncology, Boston, MA, United States.

A114 **Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study**. Eugene Lurie. Pyxis Oncology, Boston, MA, United States.

A115 **Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy**. Anthony Rodriguez. Pyxis Oncology, Boston, MA, United States.

A116 **Characterization of micvotabart pelidotin target binding properties and extracellular payload release**. Chuan Shen. Pyxis Oncology, Boston, MA, United States.

A117 **Development of multiplex immunofluorescence workflows for characterizing tumor-immune and stromal compartments for pharmacodynamic assessments of solid tumors**. Justin Trickett. Pyxis Oncology, Boston, MA, United States.

A118 **Discovery of HMPL-A251, a first-in-class HER2-directed antibody-targeted therapy conjugate (ATTC) with a novel PI3K/PIKK inhibitor payload**. Jia Hu. HUTCHMED, Shanghai, China.

A119 **ALX2004, a novel topoisomerase I inhibitor antibody-drug conjugate for the treatment of EGFR-expressing solid tumors**. Marija Vrljic. ALX Oncology, South San Francisco, CA, United States.

A120 **Topological distribution of stimulating factors on artificial antigen-presenting cells defines the therapeutic efficacyof the ex vivo expanded tumor-specific CD8+ T-cells**. Antara Mondal. National Institute of Immunology, New Delhi, India.

A121 **Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics**. Sushmita Kundu. Indian Institute of Technology Kanpur, Kanpur, India.

A122 **Elevated expression of ALPP and ALPG in KRAS-mutated pancreatic adenocarcinoma and therapeutic targeting with a bispecific T-cell engager**. Danqing Wu. EpimAb Biotherapeutics, Shanghai, China.

A123 **Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+ solid tumors in HLA-A*02:01+ patients**. Melissa Vrohlings. CDR-Life, Horgen, Switzerland.

A124 **CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior efficacy in preclinical models and improved safety in non-human primates**. Yasuaki Anami. CrossBridge Bio, Houston, TX, United States.

A125 **Devleopment of TROP2-targeted cytotoxic peptides and drug conjugates for treatment of triple negative breast cancer**. Hyeongyu Park. Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Korea, Korea, Republic of.

A126 **CDR609: A First-in-Class LGR5-targeted T Cell Engager for treatment of Colorectal Cancer and other solid tumors**. Sophie Barsin. CDR-Life, Horgen, Switzerland.

A127 **A novel Integrin beta-6-targeted antibody-drug conjugate featuring a topoisomerase I inhibitor, PBX-004 with potent antitumor activity in multiple preclinical solid tumor models**. DOO YOUNG JUNG. PINOTBIO, Suwon, United States.

A128 **Identification of peptide inhibitors of KRAS G12D and Q61H mutant protein for cancer therapy**. Dong Gyun Jo. BK21 FOUR KNU Convergence Educational Program of

Biomedical Sciences for Creative Future Talents, Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Korea, Republic of.

A129 **Bispecific antibody Ubamatamab induces personalized anti-tumor immune responses in an ex vivo platform for ovarian cancer**. Esmee Koedoot. VitroScan, Leiden, Netherlands.

A130 **A preclinical study repurposing the proteasome inhibitor carfilzomibfor use with radiotherapy and/or cetuximab for head and neck cancer**. Hanif Khan. Penn State Cancer Institute, Hershey, PA, United States.

A131 **Sigvotatug vedotin, an integrin-beta 6 directed antibody drug conjugate, demonstrates potent single-agent antitumor activity across NSCLC subtypes and the potential to combine with targeted therapies**. Gina LoMastro. Pfizer Inc, Bothell, WA, United States.

A132 **DB-1317, a novel ADAM9-targeting antibody-drug conjugate, exhibits potent antitumor activity against multiple gastrointestinal cancers**. Rong Shi. Duality Biologics, Shanghai, China.

A133 **Target clear cell ovarian cancers with ARID1A loss by combination inhibition of BRD4 and ATR**. Haineng Xu. University of Pennsylvania, Philadelphia, PA, United States.

A134 **TROP-2-Targeted ADC DB-1305/BNT325 Demonstrates Preclinical Efficacy and Early Clinical Activity in Patients with Diffuse Pleural Mesothelioma**. Michael Offin. Memorial Sloan Kettering Cancer Center, New York, United States.

A135 **GS24-B057, a potential best-in-class Nectin-4- and Trop-2-directed bispecific ADC, for the treatment of multiple solid tumors**. Meihan Li. GeneScience Pharmaceutical Co., Ltd., Changchun, China.

A136 **Comparison of the bystander effects and killing capabilities of the HER2-targeting antibody drug conjugates T-DM1 and T-DXd**. Eef Smits. Oncolines B.V., Oss, Netherlands.

A137 **GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer**. Zeng Qi. Changchun GeneScience Pharmaceutical Co., Ltd, Shanghai, China.

A138 **Extracellular FGFR1 inhibition with OM-RCA-01 humanized antibody suppresses tumor growth in FGFR1-expressing colorectal cancer models**. Ilya Tsimafeyeu. Bureau for Cancer Research - BUCARE, New York, NY, United States.

A139 **Antibody drug conjugate to a novel cell surface target for medulloblastoma**. Ginette Serrero. A&G Pharmaceutical Inc., Columbia, MD, United States.

A140 **MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3, is efficacious toward prostate cancer patient-derived xenografts**. Juniper Scribner. MacroGenics, Inc., San Mateo, CA, United States.

A141 **Incidence of pulmonary and hematologic adverse events in advanced or metastatic cancer patients treated with Datopotamab Deruxtecan: A meta-analysis of phase III randomized controlled trials**. Jason Ta. Department of Internal Medicine, HCA Healthcare / USF Morsani College of Medicine GME: HCA Florida Citrus Hospital, Inverness, FL, United States.

A142 **Risk of dermatologic adverse events with Amivantamab in EGFR-mutant non-small cell lung cancer: A meta-analysis of phase III trials**. Jason Ta. Department of Internal Medicine, HCA Healthcare / USF Morsani College of Medicine GME: HCA Florida Citrus Hospital, Inverness, FL, United States.

A143 **Toxicity profile of immune checkpoint inhibitors in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of general and hematologic adverse events from phase II and III randomized trials**. Jason Ta. Department of Internal Medicine, HCA Healthcare / USF Morsani College of Medicine GME: HCA Florida Citrus Hospital, Inverness, FL, United States.

A144 **Clinical and morphological characteristics as a predictors of the development of radioiodine resistance in thyroid cancer**. Laura Pak. National Research Oncology Center, Astana, Kazakhstan.

A145 **Restoring p53 function with novel synthetic mRNA therapy to inhibit growth of TP53-mutant tumors in synergy with taxane agents**. Seung-Hyun Shin. Hanmi Pharmaceutical Co., Ltd., Seoul, Korea, Republic of.

A146 **Novel mRNA-encoded constitutively active STING variant suppressed tumor growth in syngeneic models**. Ji Hee Lee. Hanmi Pharmaceutical Co., Ltd., Seoul, United States.

Poster Session B (To be presented October 24, 2025, 12:30-4pm ET)

B001 **Phase 1/2 trial to evaluate the safety and efficacy of PEEL-224 in combination with vincristine and temozolomide in adolescents and young adults with relapsed or refractory sarcomas**. David Shulman. Dana-Farber Cancer Institute, Boston, MA, United States.

B002 **A first-in-human, first-in-class, phase 1 trial of QEQ278 in patients with advanced solid tumors**. Christophe Le Tourneau. Department of Drug Development & Innovation (D3i), Institut Curie, Paris, France.

B003 **Orally administered MOMA-341 as monotherapy or combination therapy in participants with advanced or metastatic solid tumors: Phase 1 study design**. Charlotte Lemech. Scientia Clinical Research; School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Randwick, NSW, Australia.

B004 **Phase 1b trial of BCL-XL degrader DT2216 and weekly paclitaxel in recurrent platinum-resistant ovarian cancer**. Elizabeth Stover. Dana-Farber Cancer Institute, Boston, MA, United States.

B005 **Preliminary safety, PK and efficacy of a PARP1 selective inhibitor VB15010 in patients with advanced solid tumors in phase 1/2 study**. Charles Ding. Zhejiang Yangli Pharmaceutical Company, Hangzhou, China.

B006 **Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)**. Sumanta Pal. City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

B007 **Evaluation of deviations reported during monitoring visits in phase 1 oncology clinical trials across the NEXT Oncology site network**. Macie Lin. University of Texas at Austin, Austin, TX, United States.

B008 **TFX06 demonstrated intracranial efficacy in patients with ER+/HER2- brain metastatic breast cancer in a phase 1/2 study**. Charles Ding. Zhejiang Yangli Pharmaceutical Company, Hangzhou, China.

B009 **Trial in Progress: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/ Amplified Gastric/ Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression**. Alexandria Doerfler. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B010 **Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage repair alterations**. Philippe Pultar. Aprea Therapeutics, Inc., Doylestown, PA, United States.

B011 **Early safety and efficacy of APR-1051, a novel WEE1 inhibitor, in patients with cancer-associated gene alterations: Updated data from ACESOT-1051 phase 1 trial**. Philippe Pultar. Aprea Therapeutics, Inc., Doylestown, PA, United States.

B012 **Results From the Phase 1 Dose Escalation and Dose Expansion Study of Azenosertib, a WEE1 Inhibitor, in Patients With Advanced Solid Tumors**. Funda Meric-Bernstam. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B013 **Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)**. Alexandra Leary. Gustave Roussy Cancer Center, Villejuif, France.

B014 **CRISTAL-APC - A multi-center, open label Phase I/II study of VP-002, a C-C motif chemokine receptor 1 (CCR1) inhibitor,in combination with nab-paclitaxel and gemcitabine (nPG) inpatients withpancreatic ductal adenocarcinoma (PDAC)**. Alexander Azizi. Francis Crick Institute, London, United Kingdom.

B015 **A Phase 2 Study of Ateganosine (THIO) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced NSCLC Resistant to Prior ICI and Chemotherapy: THIO-101 Trial in Progress.**. Victor Zaporojan. Maia Biotechnology, Inc., Chicago, United States.

B016 **Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)**. Samuel Klempner. Massachusetts General Hospital, Boston, MA, United States.

B017 **Evaluation of a first-in-class dual TRPV6/AR inhibitor for the treatment of prostate cancer**. Gregory Monteith. University of Queensland, Brisbane, Australia.

B018 **TAK1 blockade induces DNA damage and immunogenic cGAS–STING pathway activation in pancreatic cancer**. Sapana Bansod. Washington University School of Medicine, St. Louis, MO, United States.

B019 **Targeting branched Lewis B/Y glycans with GNX1021: A novel ADC approach for HER2-low gastric cancer**. Yen-Ying Chen. GlycoNex Inc., New Taipei City, Taiwan.

B020 **Preclinical assessment of WRN inhibitor HS-10515 for selective targeting of MSI-H cancers**. Tzu-Pei Chang. Hansoh Bio, Rockville, MD, United States.

B021 **CBS fosters an immunosuppressive tumor microenvironment through regulation of the cGAS-STING pathway**. YONG TENG. Emory University, Atlanta, GA, United States.

B022 **FORX-428: Abest-in class PARG inhibitor with promising anti-tumor activity in preclinical cancer models**. Frank Zenke. FoRx Therapeutics AG, Basel, Switzerland.

B023 **Wild-type p53 transcriptional (Tr) readout as a vetting tool forsynthetic lethality (SL) screens incancer therapy**. Farah Mazahreh. UAMS, Little Rock, AR, United States.

B024 **Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS**. John Fischer. Cogent Biosciences Inc., Waltham, MA, United States.

B025 **The innate immune checkpoint TREX1 is a safe, effective, and druggabletarget for cancer immunotherapy**. Cong Xing. UT Southwestern Medical Center, Dallas, TX, United States.

B026 **Targeting the novel tumor antigen MT1-MMP with Bicycle® Drug Conjugates (BDC®) for the potential treatment of NSCLC and other solid tumor indications**. Gavin Bennett. BicycleTx Limited, Cambridge, United Kingdom.

B027 **TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models**. Hilary Nicholson. Tango Therapeutics, Boston, MA, United States.

B028 **Dual Oncotargeting and Immunotherapeutic Potential of USP22 Inhibition Across Diverse Human Cancers**. Deyu Fang. Northwestern University, Chicago, IL, United States.

B029 **Novel FOXM1 degrader STL001 sensitizes diverse group of human cancers to a broad-spectrum of cancer therapies**. Andrei Gartel. UIC, Chicago, IL, United States.

B030 **Development of a novel antibody drug conjugate (ADC) targeting Nectin-2 on the surface of breast cancers**. Yueyue Wang. Yale cancer center, New Haven, CT, United States.

B031 **A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)**. Samuel Klempner. Massachusetts General Hospital, Boston, MA, United States.

B032 **Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)**. Tripti Gaur. AVEO Pharmaceuticals, Inc., Boston, MA, United States.

B033 **Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial**. Moh'd Khushman. Washington University School of Medicine, St. Louis, MO, United States.

B034 **A chemoproteomic-enabled phenotypic library screen identifies KIF23 as a novel target in Ewing sarcoma.**. Hannah Walker-Mimms. Moffitt Cancer Center, Tampa, FL, United States.

B035 **NLRP3 activation drives gemcitabine-mediated metabolic changes in pancreatic cancer tumor-associated macrophages (TAMs)**. Carlo Marchetti. Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B036 **A novel PDE10 inhibitor that blocks RAS and β-catenin signaling and enhances tumor immunogenicity with robust activity to inhibit tumor growth and metastasis**. Gary Piazza. Auburn University, AUBURN, AL, United States.

B037 **RVU305, a brain-penetrant MTA-cooperative PRMT5 inhibitor, shows efficacy in GBM preclinical models**. Anna Bartosik. Ryvu Therapeutics, Kraków, Poland.

B038 **Discovery of an anticancer seed targeting cancer stem cells and analysis of its mode of action.**. Miyuki Matsui. Kyoto University, Kyoto, Japan.

B039 **APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumors**. Antoine Simoneau. Tango Therapeutics, Boston, MA, United States.

B040 **Combined treatment and metabolomics reveal mechanism underlying the synergy of ribitol and shikonin against breast cancer**. Ravi Doddapaneni. Atrium Health, Charlotte, NC, United States.

B041 **Mitochondrial antioxidant peroxiredoxin 3 is a tractable therapeutic target in mesothelioma**. Victoria Gibson. University of Vermont, Burlington, United States.

B042 **Preclinical evaluation of petosemtamab, an epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor (LGR5) bispecific antibody, on cancer stem cells**. Konstantin Slobodnyuk. Merus N.V., Utrecht, Netherlands.

B043 **Activation Lethality through the WNT/beta-catenin pathway drives efficacy in colorectal cancer**. Rebecca Lock. Delphia Therapeutics, Cambridge, MA, United States.

B044 **CBO-001, a potential first and best-in-class ADC targeting L1CAM/CD171 with potent anti-tumor efficacy in SCLC and neuroendocrine tumors.**. Dominik Brücher. CIS BIOPHARMA, Bubendorf, Basel, AB, Switzerland.

B045 **ATX-559, a first-in-class, clinical-stage DHX9 inhibitor,as a targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress**. Sunaina Nayak. Accent Therapeutics, Lexington, MA, United States.

B046 **Dimerization of SLFN12 by the PDE3A-SLFN12 complex is required for velcrin-induced toxicity in cancer cells**. Kristyna Kotynkova. Broad Institute, Cambridge, MA, United States.

B047 **Discovery of a covalent inhibitor targeting PAX8-driven ovarian cancer**. Shirley Guo. BridGene Biosciences, San Jose, CA, United States.

B048 **Fibroblast Growth Factor Receptor 2 Alterations in non-Cholangiocarcinoma Gastrointestinal Tumors**. Charbel Soueidy. Gustave Roussy, Villejuif, AB, France.

B049 **Molecular Characteristics ofKRASQ61Mutated Gastrointestinal Malignanciesand Clinical Outcomes**. Dan Zhao. MD Anderson Cancer Center, Houston, TX, United States.

B050 **Identification of novel molecular vulnerabilities in colorectal cancer through integrated transcriptomic profiling and functional genomics**. Krzysztof Brzózka. Ryvu Therapeutics, Kraków, Poland.

B051 **Discovery of SW-3431, a first-in-classmolecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers**. Goutham Narla. The University of Michigan, Ann Arbor, MI, United States.

B052 **PXG-CycK, a highly selective molecular glue degrader of Cyclin K with potent anti-tumor activity in HER2-amplified cancers**. Matthias Brand. Proxygen, Vienna, Austria.

B053 **Discovery of an allosteric, potent and selective DHX9 helicase inhibitor with best-in-class potential for the treatment of genomically unstable cancers**. Taran Khanam. Storm Therapeutics, Cambridge, United Kingdom.

B054 **Correspondence between circulating tumor DNA (ctDNA)-based ERBB2 amplification and HER2 expression by IHC/ISH across solid tumors: Molecular landscape and diagnostic implications.**. Felix Blanc-Durand. Institut Gustave Roussy, Villejuif, France.

B055 **XPO1-dependent nuclear export as a therapeutic target for ALK-positivenon-small cell lung cancers**. Maria Vittoria Di Marco. University of Torino, Torino, Italy.

B056 **Engineered T-cells, targeting overexpressed EGFR and EGFRvIII, produce complete remissions in a PDX model of human glioblastoma**. Antonella Antignani. National Cancer Institute, NIH, Bethesda, MD, United States.

B057 **Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor**. Yuting Sun. Nuvalent, Inc, Cambridge, MA, United States.

B058 **Antitumor activity and bystander killing effect of HER2 antibody-drug conjugates (ADCs) against tumors with different HER2 expression levels**. Aaron Hua. Crown Bioscience Inc., San Diego, United States.

B059 **ERBB4 heterodimers drive wild-type BRAFmelanoma cell lines**. Vipasha Dwivedi. Auburn University, Auburn, AL, United States.

B060 **Neratinib in combination with antibody–drug conjugates for patients with metastatic cancer**. Ron Bose. Washington University in St Louis, St Louis, MO, United States.

B061 **In vivo benchmarking of trastuzumab deruxtecan (T-DXd) activity in panel of 400 XPDX models**. Alyssa Simonson. START Center for Cancer Research-XenoSTART, San Antonio, TX, United States.

B062 **Loss of Flotillin-2 increases Trastuzumab emtansine internalization and cytotoxicity in HER2 amplified cancers**. Stanley Lipkowitz. National Cancer Institute, Bethesda, MD, United States.

B063 **Efficacy of amivantamab in patients with EGFR-mutated non-small cell lung cancer (NSCLC): A meta-analysis of phase 3 randomized controlled trials**. Daniel Jones. Department of Internal Medicine, Sunrise Health GME Consortium, Las Vegas, Nevada, USA, Las Vegas, NV, United States.

B064 **TRI-611, a selective, CNS-penetrant molecular glue degrader of ALK with anti-tumor activity against preclinical models of ALK-fusion positive non-small cell lung cancer including kinase inhibitor refractory tumors**. Andrew Conery. Triana Biomedicines, Inc., Lexington, MA, United States.

B065 **Using Mutations in a Dimerization Interface of ERBB4 and ERBB2 to Elucidate the Role of ERBB4-ERBB2 Heterodimers in wild-type BRAF Melanomas.**. Markelle Scott. Auburn University, Auburn, AL, United States.

B066 **Repurposed Therapeutic Targets DNA Repair and EGFR Signaling in EGFR-Mutant Lung Cancer**. Chi-Yuan Chen. Chang Gung University of Science and Technology, Taoyuan, Taiwan.

B067 **Discovery of a highly potent and selective covalent FGFR3 inhibitor**. Shirley Guo. BridGene Biosciences, San Jose, CA, United States.

B068 **A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC**. Alexander Khvat. ChemDiv Inc., San Diego, CA, United States.

B069 **Humanized cancer-specific anti-HER2 monoclonal antibodies exerted antitumor activities in human breast cancer xenograft models**. Yukinari Kato. Tohoku University Graduate School of Medicine, Sendai, Japan.

B070 **Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling**. Xiaohe Yang. North Carolina Central University, Kannapolis, NC, United States.

B071 **ALK.CAR-T cells as a new potential treatment for ALK+Merkel cell carcinoma**. Alessandro Gasparetto. University of Turin / Boston Children's Hospital, Torino, Italy.

B072 **Is targeting ERBB2-ERBB4heterodimers with monoclonal antibodies effective against wild-type BRAFmelanomas?**. Victoria Huffman. Auburn University, Auburn, AL, United States.

B073 **Targeted PhenotypeShifting or Killing Tumor Associated Macropages (TAMs) Leading toEffective Upregulation of the Immune System Response to Solid Tumors: A Comprehensive in vivo vsAI "in vivo" Assessment.**. Frederick Cope. Physis International, New Albany, OH, United States.

B074 **Combination TIGIT and PD-1 inhibition with VEGFR-2 based therapy induces potent response in patient derived immune competent xenograft model with gastroesophageal adenocarcinoma**. Sunnie Kim. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B075 **Epiregulin, a targetable niche-promoting factor, is utilized by quiescent stem-like cells within pancreatic tumors to facilitate resistance to CAR T-cell therapy**. Bryan McClellan. The University of Texas at Austin, Austin, TX, United States.

B076 **PD-L1-Targeting Peptide Synergizes Photodynamic Therapy and Immune Checkpoint Blockade for Systemic Antitumor Immunity**. Jae Myung Park. The Catholic University of Korea, Seoul, United States.

B077 **Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity**. Subhra Chakrabarty. Aurigene Oncology Ltd., Bangalore, India.

B078 **NPX125, a novel ADC targeting B7-H7, shows potent activity in solid tumors**. Emilien Loeuillard. NextPoint Therapeutic, Cambridge, MA, United States.

B079 **The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model**. Michelle Haber. Children's Cancer Institute, Sydney, Australia.

B080 **Safety and efficacy of immune checkpoint inhibitors (ICIs) among older adults with renal cell carcinoma, bladder cancer, and melanoma: visiting an understudied age group**. Ali Awada. American University of Beirut, Beirut, Lebanon.

B081 **A novel GPR68 negative allosteric modulator shows efficacy in syngeneic mouse models of colorectal cancer and modulates the immunosuppressive phenotype of colorectal fibroblasts**. Matilda Bingham. Cumulus Oncology, Edinburgh, United Kingdom.

B082 **Assessment of prevalence and utilization of tumor mutational burden and microsatellite instability in cancer patients at a community cancer center**. Safwan Muhammad. Bayhealth Hospital, Dover , DE, Dover, DE, United States.

B083 **Transcription factors enhancing anti-tumor chemokine expression and lymphocyte infiltration in KRAS G12C inhibitor-resistant non-small cell lung cancer.**. Chendi Li. Massachusetts General Hospital Cancer Center, Charlestown, MA, United States.

B084 **Clinical Outcomes and Biomarker Correlates of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Novel Immunotherapies in Phase 1 Trials**. Harold Tan. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B085 **Lysosome-dependent ferroptosis induced by a fully human anti-B7-H4 antibody overcomes primary resistance to PD-1 blockade**. Renlu Zhang. Institute of Immunotherapy, Fujian Medical University, Fuzhou, China.

B086 **Anchored in Resistance: Overcoming Nidogen-2 (NID2) - mediated Immunoresistance in Ovarian Cancer with Ras and Bcl-xl Inhibition**. Fabian Kraus. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der Universität München, Ludwig-Maximilians-Universität (LMU), Munich, Germany and Massachusetts General Hospital - The Vincent Center for Reproductive Biology, Harvard Medical School, Boston, MA, United States.

B087 **A translational platform of patient-derived xenografts (PDXs) for upper gastrointestinal cancers**. Daniel Sin Coscujuela. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

B088 **Development of a silk-alginate-based 3-dimensional tumor model to screen anti-cancer drugs: Targeting S1P signaling for oral cancer therapy**. Ashok Kumar. All India Institute of Medical Sciences, Bhopal, Bhopal, India.

B089 **Development, characterization, and humanization of NCI-N87 human gastric carcinoma xenograft model in NSG mice**. Hillary Millar Quinn. Labcorp Discovery Oncology, Ann Arbor, MI, United States.

B090 **Radiation-induced oral mucositis to rapidly determine effective radiosensitizing dosing regimens for ATM and DNAPK inhibitors**. Danielle Burgenske. Mayo Clinic, Rochester, MN, United States.

B091 **Establishment and characterization of a panel of naive and pretreated brain cancer XPDX models**. Alyssa Simonson. XenoSTART, San Antonio, TX, United States.

B092 **A preclinical ex vivo model for glioblastoma captures patient heterogeneity in drug response**. Ezgi Kaya Aksoy. Crown Bioscience Netherlands, Leiden, Netherlands.

B093 **Enhanced ctDNA extraction with quaternary ammonium salt integrated in a ctKRAS prototype assay significantly improves sensitivity for detecting low-allelic frequency KRAS mutations in plasma**. Anthony Green. Biocartis US Inc., Itasca, IL, United States.

B094 **Modelling ADC sensitivity and mode-of-action in human cancer derived organoids**. Marten Hornsveld. Crown Bioscience, Leiden, Netherlands.

B095 **A Novel Machine Learning Technique Accurately Predicts Drug Response in Colorectal Microorganosphere Droplets**. Michael Rutenberg Schoenberg. Xilis Inc, Durham, NC, United States.

B096 **Response to approved anticancer drugs by multi-cell type tumor spheroids versus organoids derived from the same clinical specimen: a comparison analysis**. Beverly Teicher. National Cancer Institute, Bethesda, MD, United States.

B097 **Structural Interpretations of High-throughput PI3K Pathway CRISPR Base-editing Data**. Mathew Garnett. Wellcome Sanger Institute, Cambridge, United Kingdom.

B098 **A High-Throughput RNA-Based Screening Platform for Matching Patients to Antibody-Drug Conjugate Trials**. Hui Chen. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B099 **BTK-EndoMut Platform: Engineered Resistance Models Accelerating BTK-Targeted Drug Discovery**. Thomas Strong. Kyinno Biotechnology Boston Inc., woburn, MA, United States.

B100 **Molecular and pharmacological profiling of PDX breast cancer models and their cellular counterparts to identify resistance mechanisms and novel therapeutic options**. Olivier Déas. XenTech, Evry-Courcouronnes, France.

B101 **Subclonal drift predicts tumor response to treatment**. Arijit Chakravarty. Fractal Therapeutics, Inc., Lexington, MA, United States.

B102 **Using subclonal dynamics to detect and quantify fitness advantages of resistant subclones in tumors under treatment**. Arijit Chakravarty. Fractal Therapeutics, Inc., Lexington, MA, United States.

B103 **Optim.AI 2.0™: An immune-integrated functional precision platform for predicting combinatorial immunotherapy response**. Edward Chow. KYAN Technologies Pte Ltd, Singapore, Singapore.

B104 **A smarter route to the brain:Preserving the BBB in preclinical brain tumor models**. Cheryl Davis. Reaction Biology, Hershey, PA, United States.

B105 **Oral small molecule MYC condensate modulators (c-mods) induce robust anti-tumor responses in preclinical solid tumor models**. Yufei Xu. Dewpoint Therapeutics, Boston, MA, United States.

B106 **NASH as a Silent Threat: Impaired Survival in Relapsed/Refractory Myeloma Patients Treated with Teclistamab**. Allen Seylani. Cleveland Clinic, Cleveland, OH, United States.

B107 **Preclinical activity of ARV-806, a PROTAC KRAS G12D degrader**. Katie Smith. Arvinas Operations, Inc., New Haven, CT, United States.

B108 **NTS231 is a novel covalent allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex that selectively degrades NRF2 and inhibits tumors with aberrant NRF2 activation**. Guoqiang Zhou. Nutshell Therapeutics, Shanghai, China.

B109 **Identification of small molecule activators targeting the JH2 pseudokinase domain of TYK2**. Hirokazu Matsumoto. Carna Biosciences, Inc., Kobe, Japan.

B110 **A novel BRD4 degrader, MT-4561, degrades the BRD4-NUT fusion protein in vitro and induces complete tumor regression in a subcutaneous NUT carcinoma xenograft model**. Masahiko Tokura. Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan.

B111 **Risk of pancreatitis and autoimmune hepatitis among patients with breast cancer receiving 5-years of aromatase inhibitor therapy vs.tamoxifen**. Allen Seylani. University of California, Riverside, Riverside, CA, United States.

B112 **Targeting Pancreatic Cancer Through Immune Activation and Lifestyle Modification**. Aariyana Britton. n/a, Wakefield, VA, United States.

B113 **Novel thiosemicarbazones demonstrate pronounced anti-tumor activity inmarginal zone lymphoma models, also overcoming resistance to targeted agents**. Francesco Bertoni. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

B114 **Clinical-stage Wnt/β-catenin antagonist peptide ST316, suppresses colorectal cancer tumor growth by promoting BCL9 degradation**. Lila Ghamsari. Sapience Therapeutics, Inc., Tarrytown, NY, United States.

B115 **Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) estrogen receptor (ER) degrader, induces greater ER degradation and antitumor activity relative to selective ER degraders (SERDs) in preclinical ER+ breast cancer models**. Madeline Dorso. Arvinas Operations, Inc., New Haven, CT, United States.

B116 **Robust efficacy and favorable safety profile of pan-TEAD inhibitors in oncogenic Hippo pathway-dysregulated cancers including mesothelioma**. Jisook Kim. Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of.

B117 **Discovery of potent, selective, and orally bioavailable heterobifunctional EP300 degraders**. Yongtaek Lee. Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of.

B118 **Through hit synergy and beyond! Integrating hit finding and direct to biology to shorten time to development candidate.**. Alexandra Stowell. Sygnature Discovery, Nottingham, United Kingdom.

B119 **FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasibresistant PDX models**. Yan Wang. Frontier Medicines, Boston, MA, United States.

B120 **Development of PROTACs for targeted degradation of FGFR3-TACC3 oncofusions**. Eugen Dhimolea. Albert Einstein College of Medicine, Bronx, NY, United States.

B121 **PROTAC-mediated degradation of TACC3 enhances the efficacy of anti-mitotic drugs in cancer**. Eugen Dhimolea. Albert Einstein College of Medicine, Bronx, NY, United States.

B122 **Activity of the novel KIF18A Inhibitor, ATX-295, is enriched in whole genome doubled ovarian and TNBC preclinical models**. Laura Ghisolfi. Accent Therapeutics, Lexington, MA, United States.

B123 **FMC-220, a highly potent and selective covalent activator of p53 Y220C, is broadly active in p53 Y220C containing PDX models across cancer indications**. Kevin Webster. Frontier Medicines, Boston, MA, United States.

B124 **YTHDC1 inhibition as a therapeutic strategy with potent preclinical activity alone and in combination with BCL-2 inhibitors**. Shilpi Arora. Transition Bio, Cambridge, MA, United States.

B125 **Discovery of a first-in-class CDK9 degrader targeting oncogenic transcription networks in hematologic and solid tumors**. Mario DiPaola. Therabene Inc, Norwood, MA, United States.

B126 **The effects of Amaryllidaceae plant constituents narciclasine, lycorine and haemanthamine on chronic lymphocytic leukemia cells**. Alexander Kornienko. Texas State University, San Marcos, TX, United States.

B127 **Unravelling the chemotherapeutic potential of taxifolin ruthenium-p-cymene complex in breast carcinoma and its repurposing in colon cancer**. Barshana Bhattacharya. Bengal College of Pharmaceutical Technology, Birbhum, WA, India.

B128 **CS-01: a next-generation active immunotherapy that depletes epidermal growth factor in squamous NSCLC**. Theresa Zhang. CelSiege Biosciences Inc., Boston, MA, United States.

B129 **DUP5, a novel mRNA translation inhibitor as a payload for antibody drug conjugates, exhibits promising preclinical efficacy**. Rong Shi. Duality Biologics, Princeton, NJ, United States.

B130 **DUP9, a novel ecteinascidin derivative, as a payload for antibody drug conjugates, exhibits promising preclinical efficacy**. Rong Shi. Duality Biologics, Princeton, NJ, United States.

B131 **Radio-activated Nanoactivators Targeting Folate Receptors induce Mitochondrial Dysfunction and Reframe Immune Tumor Microenvironment in Pancreatic Cancer**. Wen-Pin SU. National Cheng Kung University, Tainan, Taiwan.

B132 **SD-1240, a VHL-based STAT3 degrader, induces optent and selective STAT3 depletion and suppresses tumor growth in ALCL preclinical models**. Longchuan Bai. University of Michigan, Ann Arbor, MI, United States.

B133 **Characterization of FDA Regulatory Designations and Trial Models for Rare Cancer Approvals (2012–2022)**. Tariq Alzahrani. Saudi FDA, Riyadh, Saudi Arabia.

B135 **Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response**. Aundrietta Duncan. Iterion Therapeutics, Houston, TX, United States.

B136 **Degrader-Antibody Conjugate Platform: Experimental Capabilities in Characterization and Evaluation – From In Vitro Assays to In Vivo Studies**. Tiejun Bing. ICE Bioscience, Beijing, China.

B137 **Advancing ADC Development: Dual-Payload Toxicity Assessment Using a Cancer Cell Panel and ADC Resistant cell lines**. Tiejun Bing. ICE Bioscience, Beijing, China.

B138 **High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids**. Thomas Dexheimer. Frederick National Laboratory for Cancer Research, Frederick, MD, United States.

B139 **A panel of patient-derived organoid models from rare cancers for high-throughput preclinical pharmacology studies**. Nathan Coussens. Frederick National Laboratory for Cancer Research, Frederick, MD, United States.

B140 **Development of EO-4426: A brain-penetrant dual DNA polymerase-α and ribonucleotide reductase inhibitor**. Jeffrey Bacha. Edison Oncology Holding Corp, Menlo Park, CA, United States.

B141 **Degradation of the ETS transcription factor ERG by stabilized helical peptide (Helicon™) degraders enables pharmacological validation in ERG-fusion prostate cancer models.**. Amelia Luciano. Parabilis Medicines, Cambridge, MA, United States.

B142 **EO3001: A novel agent for ARID1A mutant cancers**. Dennis Brown. Edison Oncology Holding Corp., Menlo Park, CA, United States.

B143 **Discovery of Helicon Peptides for the Selective Degradation of the Agonist-Bound Conformation of Androgen Receptor (ARON) in Prostate Cancer**. Diwakar Pattabiraman. Parabilis Medicines Inc, Cambridge, MA, United States.

B144 **Genomic characterization and clinical outcomes in MDM2-amplified biliary tract cancers**. Sundas Nasir. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Poster Session C (To be presented October 25, 2025, 12:30-4pm ET)

C001 **Investigating anti-cancer compounds and the mechanism activated to induce cell death**. Allison Elias. University of Texas at El Paso, EL PASO, TX, United States.

C002 **Reverse Transcriptase Inhibition Enhances Demethylation-Induced Immune Activation and tumor cell toxicity in HPV+ OPSCC**. Sri Vemulamanda. UNC school of medicine, Chapel Hill, NC, United States.

C004 **ADC screening platform, a useful platform for ADC drug evaluation**. Thomas Strong. Kyinno Biotechnology Boston Inc., woburn, MA, United States.

C005 **Arylsulfatase B inhibits progression of malignant melanoma by COP1-mediated apoptosis in syngeneic and humanized mouse models**. Joanne Tobacman. University of Illinois Chicago and Jesse Brown VAMC, Chicago, IL, United States.

C006 **Fitness landscape modeling indicates decreased effectiveness of microtubule assembly targeting drugs in tumors demonstratingchromosomalinstability (CIN)**. Arijit Chakravarty. Fractal Therapeutics, Inc., Lexington, MA, United States.

C007 **Expanding Chemical Space: Discovery of Novel PARP Inhibitors Using Diverse Pharmacophore-Based Screening**. Alberto Ocana. Hospital Clínico San Carlos, Madrid, Spain.

C008 **Validation of an AI-powered computational chemistry workflow for streamlined drug discovery**. Cristian Privat. Hospital Clínico San Carlos, Madrid, Spain.

C009 **Development of an innovative anticancer drug TBP1901, an injectable prodrug of curcumin, for the treatment of multiple myeloma**. Hideaki Kakeya. Kyoto University, Kyoto, Japan.

C010 **A novel T-cell engager prodrug platform achieves dual masking by a single VHH domain for balancing efficacy and safety in solid tumor therapy**. Xiaofang Wen. Zhejiang Doer Biologics Co., Ltd., HANGZHOU, China.

C011 **Discovery of novel SMARCA2 small molecule inhibitors with best-in-class potency and selectivity for the treatment of SMARCA4-mutant cancers**. Lijs Beke. Onco3R Therapeutics, Leuven, Belgium.

C012 **Discovery of a Best-in-Class small molecule p53 Y220C reactivator: Breaking through the potency ceiling**. Francois Gonzalvez. Onco3R Therapeutics, Leuven, Belgium.

C013 **Discovery of novel functional allosteric pockets on p53 using the AMPS screening platform**. Jonathan Ipsaro. Atavistik Bio, Cambridge, MA, United States.

C014 **Overcoming chemoresistance in ovarian cancer through therapeutic targeting of Oxysterol-Binding Proteins (OSBP/ORP4)**. Swati Choudhary. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

C015 **A STAT3 PROTAC Degrader SD-1240: the Structure-based Design, the Structure Mechanism ofPotency andSelectivity, and the Mechanism of Action of Anti-tumor Activity**. Haibin Zhou. University of Michigan, Ann Arbor, MI, United States.

C016 **Model-optimized bispecific antibodies improve antibody-drug conjugate localization to tumors**. Madison Stoddard. Fractal Therapeutics, Lexington, MA, United States.

C017 **Preclinical evaluation of EZH2 inhibitor tazemetostat-based combination therapies to treat lymphoma and solid tumors**. Huijing Yu. HUTCHMED Limited, Shanghai, China.

C018 **Dissecting the Role of H3K4me3 in Transcriptional Activation Using a Dual-Inducible CRISPR-Based Epigenetic Effector Recruitment System**. Chenwei Zhou. Case Western Reserve University, Cleveland, OH, United States.

C019 **Prime editing of DNMT3A to assess mutants rescuing the R882H hotspot mutation**. Luke Chen. Harvard University, Cambridge, MA, United States.

C020 **Discovery of novel SMARCA2 degraders with synergistic activity against SMARCA4 and KRAS co-mutant tumors.**. Yonathan Lissanu. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C022 **Dual KAT6/7 inhibition delivers robust monotherapy anti-tumor activity in biomarker selected indications and disrupts emergence of drug-tolerant persister cell populations**. Manav Gupta. Ideaya Biosciences, SOUTH SAN FRANCISCO, CA, United States.

C023 **Development of isogenic models of marginal zone lymphoma for therapeutic target discovery in TET2-deficient disease**. Afua Mensah. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C024 **CBP/EP300 inhibitorOPN-6602inmarginal zone lymphomas: preclinical activity as a single agent and in combination with BTK inhibition**. Alberto Arribas. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C025 **Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers**. Susanta Samajdar. Aurigene Oncology Limited, Bangalore, India.

C026 **Epigenetic silencing of MTAP defines a distinct class of PRMT5-inhibitor-sensitive cancers**. Luis Álvarez. Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada-Nemesio Diez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain., Madrid, Spain.

C027 **Epigenetic vulnerabilities in marginal zone lymphoma**. Alberto Arribas. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C028 **Targeted Degradation of EZH2 Disrupts PRC2 Integrity and Suppresses Breast and Ovarian Tumor Progression**. Alberto Ocana. Hospital Clinico San Carlos, Madrid, Spain.

C029 **PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer**. Shikhar Sharma. Pfizer, San Diego, CA, United States.

C030 **Functional characterization of VS-186B, a novel HDAC inhibitor for cancer treatment**. Laura Sanchez-Michael. University of Texas at El Paso, El Paso, TX, United States.

C031 **Disarming colorectal plasticity: Dual HDAC1/2 inhibition reprograms tumor cell fate via H3K27ac-dependent differentiation**. Nilay Sethi. Dana-Farber Cancer Institute, Boston, MA, United States.

C032 **PRC2 inhibition enhances AR inhibitor response to delay treatment relapse in castration-sensitive prostate cancer by restricting adaptation of tumor cells in preclinical studies**. Anneleen Daemen. ORIC Pharmaceuticals, Inc., South San Francisco, CA, United States.

C033 **EZH2 regulates cell identity in neuroendocrine-like prostate cancer by driving alternate transcription via activation of translation and RNA processing regulation**. Leigh Ellis. Center for Prostate Disease Research, Bethesda, MD, United States.

C034 **Beyond genomics: Integrative multi-omics in cancer research**. Ana Robles. National Cancer Institute, Rockville, MD, United States.

C035 **Arrayed CRISPR Screening Reveals EFNA1 as a Non-Cell-Autonomous Essential Gene in Pancreatic Cancer Cells**. Xingyi Shi. Novartis BioMedical Research, Cambridge, MA, United States.

C036 **Comprehensive chordoma cell systems: Profiling brachyury-independent persistence and stem-like transitions in novel patient-derived sacral culture models**. Beatrice Campilan. Brown University Health, Providence, RI, United States.

C037 **Comprehensive genomic profiling in central nervous system tumors reveals low frequency of deleterious alterations in SETD2 without associated increase in mutational burden.**. Tine Østergaard. Rigshospitalet, Copenhagen, Denmark.

C038 **Mitochondrial genetic variation orchestrates COPZ1 transcript heterogeneity and reveals telomere-mediated vulnerabilities in osteosarcoma**. Kole Joachim. David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States.

C039 **A pan-cancer map of paralog dependencies reveals novel synthetic lethal targets and biomarker-defined vulnerabilities**. William Sellers. Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, MA, United States.

C040 **Real-world characterization of PTK7, an oncofetal pseudokinase expressed in multiple solid tumors**. Grace Dy. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

C041 **Highly sensitive protein quantification in cancer models using antibody-based proteomics**. Xiaomeng Zhang. Broad Institute, Cambridge, MA, United States.

C042 **Systematic discovery of logic-gated cell surface targets for enhanced solid tumor CAR therapy through single-cell transcriptomics**. Sanna Madan. National Cancer Institute, Bethesda, MD, United States.

C043 **PIN1 mRNA expression in biliary tract cancer: A multiomic analysis of its prognostic relevance and association with tumor-immune states in a large real-world cohort**. Justin Lo. Vanderbilt University Medical Center, Nashville, TN, United States.

C044 **A Comparative Evaluation of Preclinical Models—Cell Lines, Organoids, and PDX—for Informed Model Selection**. Zixuan Xie. Crown Bioscience, Suzhou, China.

C045 **Exploring EGLN1/PHD2 role in KRAS mutated lung cancer: insights into mitochondrial modulation and therapeutic opportunities**. Valentina Sancisi. Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

C046 **Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study**. Marc Fellous. PMV Pharmaceutical, Princeton, NJ, United States.

C047 **Unraveling proteotoxic and oxidative stress - driven adaptations in multiple myeloma**. Ioannis Trougakos. Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.

C048 **Chemoproteomic-enabled fragment-based drug discovery target identification in small cell lung cancer**. Vanessa Camara Fernandes. Moffitt Cancer Center, Tampa, FL, United States.

C049 **IMTAC™: A proteome-wide live-cell screening platform for discovering covalent binders to diverse targets including GPCRs, phosphatases, and more**. Shirley Guo. BridGene Biosciences, San Jose, CA, United States.

C050 **GDF15 mRNA expression in biliary tract cancer (BTC): a multiomic analysis of its prognostic relevance and association with tumor-immune states in a large real-world cohort**. Thatcher Heumann. Vanderbilt University Medical Center, Nashville, TN, United States.

C051 **Emerging Novel Targets to treat non-responding HER2-negative breast cancer patients: The neoadjuvant I-SPY2 TRIAL 2300 patient Omicsdata and organoid studies**. Laura van t Veer. University California San Francisco, San Francisco, CA, United States.

C052 **Integrated pharmacological analysis of patient-derived colorectal cancer tumoroids reveals strong predictive associationsto approved therapies andnovel combination therapies**. Jarle Bruun. Oncosyne, Oslo, Norway.

C053 **Acrivon Therapeutics' generative ensemble model (KaiSR) accurately predicts and expands proprietary, actionable kinase-substrate relationships globally for the human kinome**. Corey Xu. Acrivon Therapeutics, Inc., Watertown, MA, United States.

C054 **Clinical Utility of Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors**. Burak Uzunparmak. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C055 **Incidence of gastrointestinal adverse events in advanced or metastatic cancer patients treated with Datopotamab Deruxtecan: A meta-analysis of phase III randomized controlled trials.**. Ramaditya Srinivasmurthy. Department of Internal Medicine at Mount Sinai Morningside/West, New York, NY, United States.

C056 **Risk of Immune-related adverse events with immune checkpoint inhibitors in locally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials.**. Ramaditya Srinivasmurthy. Department of Internal Medicine at Mount Sinai Morningside/West, New York, NY, New York, NY, United States.

C057 **Locoregional toxicities associated with immunotherapy plus chemoradiation in locally advanced head and neck cancer: A meta-analysis of phase 3 trials.**. Ramaditya Srinivasmurthy. Department of Internal Medicine at Mount Sinai Morningside/West, New York, New York, NY, United States.

C058 **ADORA2B Inhibition in Mesothelioma (MMe) cells affects PDL-1 expression, exerts an effective response on Hyppo andAKT signaling and elicits anti-tumor immune response**. luciano Mutti. L' Aquila University, L 'Aquila, Italy.

C059 **Development of a Differentiated, Best-in-Class Oral Cbl-b Inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy**. Susanta Samajdar. Aurigene Oncology Ltd, Bangalore, India.

C060 **Discovery of a novel IL4I1 inhibitor by high-throughput screening of the SymeGold library**. Guido Zaman. Oncolines B.V., Oss, Netherlands.

C061 **Real-World Outcomes of Immune Checkpoint Inhibitors and Emerging Immunotherapies in Molecularly Characterized NSCLC Treated in a Phase 1 Clinical Trial Unit.**. Paula Rodríguez-Hernáez. University Hospital Nuestra Señora de Candelaria, Santa Cruz Tenerife, Spain.

C062 **MED12 loss promotes PD-L1–mediated immune evasion and predicts response to immune checkpoint inhibitors in NSCLC**. Hyun-Min Ryu. Asan Medical Center, Seoul, United States.

C063 **Discrepancies Between Calculated and Actual Creatinine Clearance: A Phase 1 Trial Unit Experience**. Mohamed Gouda. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C064 **Anemia, transfusions, and health-related quality of life in patients with advanced-stage classic Hodgkin lymphoma receiving multiagent therapy: Findings from the HD21 study**. Fjoralba Kristo. Takeda Development Center Americas, Inc., Cambridge, MA, United States.

C065 **Research biopsy participation and safety in cancer therapeutic trials**. Taiwo Adesoye. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C066 **Molecular subtyping of NCI PDMR models using gene expression profiles**. I-Fan Wu. Frederick National Lab, Frederick, MD, United States.

C067 **Screen failures in early-phase oncology trials: A single-center UK analysis of decentralized recruitment methods**. Francis Young. The Christie, Manchester, United Kingdom.

C068 **HPV+ and HPV- Head and Neck Cancer Patient-derived Models in the NCI Patient-Derived Models Repository**. Yvonne Evrard. Frederick National Laboratory for Cancer Research, Frederick, MD, United States.

C069 **Real World Experience of Recurrence Score Oncotype Dx in Adjuvant Treatment of patients with HR+ HER2- Early Breast Cancer: Delays of initiation of adjuvant chemotherapy in patients with high scores**. Ali Awada. American University of Beirut Medical Center, Beirut, Lebanon.

C070 **Evolving Paradigms and shifting priorities in the landscape of Phase 1 Oncology Trials: 2021–2024**. Deepak Bhamidipati. Sarah Cannon Research Institute, Nashville, TN, United States.

C071 **ICESTP SAFETYPANEL™: From Off-Target Identification to Clinical Risk Management**. Tiejun Bing. ICE Bioscience, Beijing, China.

C072 **Comparing and combining existing radiological criteria for hyperprogressive disease in patients receiving immune-oncology therapy: Building towards a sensitive and conservative method to assess the presence of hyperprogressive disease.**. Emiliano Calvo. START Madrid-CIOCC, Madrid, Spain.

C073 **Heritable resistance and phenotypic stochasticity are likely drivers of irreproducibility in experimental determination of in vitro potency of anticancer agents**. Madison Stoddard. Fractal Therapeutics, Lexington, MA, United States.

C074 **Dual NR4A1/2 ligands inhibit rhabdomyosarcoma cell growth and trigger ferroptosis by activating CD71**. Arafat Rahman Oany. Texas A&M University, College Station, TX, United States.

C075 **Study of L-Asparaginase Per-Day Decline and Its Association with Measurable Residual Disease (MRD) in Pediatric Acute Lymphoblastic Leukemia (ALL)**. Bijurica Chakraborty. Nil Ratan Sircar Medical College & Hospital (NRSMCH), Kolkata, IN, India.

C076 **Clinical pharmacokinetic/pharmacodynamic relationship for AB598, a large molecule inhibitor of CD39**. Lilian Adeojo. Arcus Biosciences Inc, Hayward, CA, United States.

C077 **GenSci143, a Novel B7-H3 × PSMA Bispecific Antibody-Drug Conjugate (BsADC), Demonstrates Broad-Spectrum Preclinical Antitumor Efficacy with a Favorable Safety Profile**. Liang Xu. GeneScience Pharmaceutical Co., Ltd., Shanghai, China.

C078 **DNA Nanocarrier-mediated Co-Delivery of Cisplatin and Silibinin for enhanced treatment of Oral Squamous Cell Carcinoma**. Kanisha Shah. Ahmedabad University, Ahmedabad, India.

C080 **Lipid raft-mediated insulin signaling sustains AKT activation and contributes to osimertinib resistance in NSCLC cells**. Ching-Chow Chen. Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei, Taiwan.

C081 **Lipid raft-mediated insulin signaling sustains AKT activation and contributes to osimertinib resistance in NSCLC cells**. Tine Wyseure. Vividion Therapeutics, San Diego, CA, United States.

C082 **BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia**. Kerstin Sinkevicius. BBOT, South San Francisco, CA, United States.

C083 **Targeting anoikis resistance: The role of Tropomyosin2.1 in breast cancer cell survival**. Nehal Dwivedi. The University of Texas Medical Branch Galveston, Galveston, TX, United States.

C084 **The farnesyl transferase inhibitor KO-2806 constrains mTORC1 activity to enhance the antitumor efficacy of mutant-selective PI3Kα inhibitors**. Alison Smith. Kura Oncology, San Diego, CA, United States.

C085 **Discovery and Preclinical Development of Best-in-Class Superpotent Superselective mTOR Inhibitors for Cancer Treatment**. Asier Unciti-Broceta. University of Edinburgh, Edinburgh, United Kingdom.

C086 **First-in-class PI3Kα-targeting degrader antibody conjugates (DACs) for selective and safer treatment of PI3Kα-driven cancers**. Wei He. Accutar Biotechnology, INC., Cranbury, NJ, United States.

C087 **Drugging UBXN2A, a tumor suppressor protein in colorectal cancer: Selective suppression of mTORC2-AKT pathway in patient-derived xenograft cells**. Morgan Montgomery. University of South Dakota, Vermillion, SD, United States.

C088 **IntelligentHitDiscoveryPlatformforAcceleratedCyclicPeptideRadiopharmaceuticalDevelopment**. Tiejun Bing. ICE Bioscience, Beijing, China.

C089 **Somatostatin directed radiopharmaceutical therapy for medulloblastoma spares healthy brain radiation**. Saad Sheikh. University of Pittsburgh, Pittsburgh, PA, United States.

C090 **Development of a multi-functional CAIX-TGFβ targeted radiopharmaceutical for triple-negative breast cancer**. Wonjong Jin. University of Wisconsin, Madison, WI, United States.

C091 **Validation of the U87MG human glioblastoma cell line xenograft model as a platform for the development of radioligand therapy and othertargeted therapeutics**. Michael Batey. Perceptive, Boston, MA, United States.

C092 **ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, demonstrates potent anti-tumor activity and overcomes osimertinib resistance in lung cancer models**. Adeela Kamal. Actinium Pharmaceuticals, Inc., New York, NY, United States.

C093 **In Silico Virtual Microdosimetry Analysis of Spatial Transcriptomics Data Identify Combination Strategies for PSMA Trageted Radionuclide Therapy**. Hongyoon Choi. Seoul National University Hospital, Seoul, United States.

C094 **Tumor-associated fibroblasts drive taurine accumulation and radiotherapy resistance in renal cell caecinoma via the CXCL12/CXCR4/SLC6A6 axis**. Qiwen Pan. Sun Yat-sen University Cancer Center, guangzhou, China.

C095 **[212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs)**. Vikas Prasad. Washington University School of Medicine, St. Louis, United States.

C096 **Improving patient management in mCRPC: Combined in vitroalpha particle and x-ray radiotherapies with Enzalutamide**. John Van Wazer. Washington University in St. Louis, School of Medicine, St. Louis, MO, United States.

C097 **Evolution of global radiopharmaceutical clinical trials in oncology: A data-driven analysis of historical and current trends**. Iaguru Andrei. Stanford University, Stanford, CA, United States.

C098 **Overexpression of glycoprotein non-metastatic melanoma protein B (GPNMB) in esophageal cancer cells is mediated through a miR-29a-3p-TFEB axis**. Pornima Phatak. Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, United States.

C099 **The Long non-coding RNA CD2BP2-DT enhances cell cycle progression and promotes cancer cell growth via regulation of MAPK8IP2 expression.**. Doron Ginsberg. Bar Ilan University, Ramat Gan, Israel.

C100 **Therapeutic targeting of microRNA-31 promotes chemosensitivity via ATOX1 in pancreatic ductal adenocarcinoma**. David Hackett. Trinity College Dublin, Dublin, Ireland.

C101 **Systematic functional profiling of long noncoding RNAs identifies therapeutic vulnerabilities in doxorubicin-resistant triple-negative breast cancer**. Vishnubalaji Radhakrishnan. Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar.

C102 **MCAT™: A 3D cancer functional genomics platform uncovers clinically predictive novel targets for Hepatocellular Carcinoma beyond traditional differentially expressed genes (DEG) and 2D cancer models**. Frances Kim. Medic Life Sciences, Palo Alto, CA, United States.

C103 **Inhibition of MGAT1 overcomes STK11-driven immune evasion in non-small cell lung cancer**. Kiera Vassallo. Tango Therapeutics, Boston, MA, United States.

C104 **Hit finding and assay enablement for MGAT1, a novel glycosyl transferase involved in cancer cell immune evasion.**. Katarzyna Handing. Tango Therapeutics, Boston, MA, United States.

C105 **Gain of function cDNA screen identifies SIK3 activation as a therapeutic strategy for STK11 mutant cancer**. Teng Teng. Tango Therapeutics Inc., Boston, MA, United States.

C106 **Validated novel Immuno-therapeutic targets for lung cancer revealed by SpliceIOTM- Innovative platform that identifies disease-specific alternative splicing**. Sakshi Gera. Envisagenics, New York, NY, United States.

C107 **Characterizing PTEN mRNA expression in patient-derived chordoma cell lines**. Golara Malaki. Brown University, Providence, RI, United States.

C108 **The therapeutic candidate antibody PODO447 recognizes a glycopeptide on podocalyxin-expressing tumor cells that have undergone a partial epithelial-mesenchymal transition**. Pamela Austin Dean. University of British Columbia, Vancouver, BC, Canada.

C109 **Cytomegalovirus reactivation drives brain metastasis in breast cancer and reveals a targetable therapeutic axis**. Wenjuan Dong. houston methodist research institute, Houston, TX, United States.

C110 **Revealing Hidden Off-target Risks of CTLA-4: A High-Sensitivity Assessment via the MPSA-AB5000 Platform**. Thomas Strong. Kyinno Biotechnology Boston Inc., Woburn, MA, United States.

C111 **RAS-mutant tumor-selective inhibition of dimeric RAF by a novel Type 1 RAF inhibitor**. Desaunay Mathieu. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

C112 **ACR-2316 is a novel, differentiated, clinical-stage WEE1/PKMYT1 inhibitor designed by Acrivon's Generative Phosphoproteomics AP3 Platform for optimal pro-apoptotic pathway effects in tumor cells resulting in superior preclinical activity**. Portia Lombardo. Acrivon Therapeutics, Watertown, MA, United States.

C113 **Discovery of Best-in-Class FGFR3 small molecule inhibitors with high isoform selectivity and activity against gatekeeper mutations**. Sandrine Vendeville. Onco3R Therapeutics, Leuven, Belgium.

C114 **Discovery of a Novel, Selective Brain-Penetrant CDK2 inhibitor for targeted cancer therapy**. Boris Rogovoy. Padarn Therapeutics, Dover, DE, United States.

C115 **In vitro and in vivo screening platform for discovery of JAK2 inhibitors**. Feng Hao. Kyinno Biotechnology, Woburn, MA, United States.

C116 **Novel ATR inhibitors with CNS penetrance developed by artificial intelligence**. Mads Daugaard. Rakovina Therapeutics, Vancouver, BC, Canada.

C117 **Understanding the implications of CD36 expression in Hormone Receptor+/HER2-(HR+/HER2-) Drug Tolerant Persister breast cancer**. Alexys Gayne. Dartmouth College, Hanover, NH, United States.

C118 **A Non-Canonical role of cGMP Links PDE5A Inhibition to Metastasis Suppression**. Yarden Ariav. The weizmann institute of science, Rehovot, Israel.

C119 **E7130's tumor microenvironment ameliorating activity enhances treatment efficacy in urothelial carcinoma.**. Takanori Abe. Eisai Co., Ltd., Ibaraki, Japan.

C120 **TACC3 is a driver of metastasis in centrosome-amplified breast cancer**. Kubra Calisir Unsal. Medical University of South Carolina, Charleston, SC, United States.

C121 **Single-cell RNA profiling reveals metastatic capacityof the malignant cells underlying microvascular invasion in patients with hepatocellular carcinoma**. Yeseong Hwang. Yonsei University College of Medicine, Seoul, United States.

C122 **Effects of standard-of-care therapies on tumor growth, tumor-induced bone loss and bone pain in preclinical models of breast and prostate cancer bone metastasis and multiple myeloma bone disease**. Tiina Kähkönen. OncoBone Ltd, Kiviniemi, Finland.

C123 **Discovery and characterization of novel pre|CISION® technology compounds delivering complementary dual warheads to the tumor microenvironment following FAP cleavage**. Francis Wilson. Avacta Life Sciences, London, United Kingdom.

C124 **MCAT™: A 3D Co-Culture Platform for Genome-Wide CRISPR Screening to Identify Stromal-Driven Vulnerabilities in CMS4 Colorectal Cancer**. Pranay Agarwal. Medic life sciences, Palo Alto, CA, United States.

C125 **Chitinase 3-like-1 as an immunosuppressive modulator in chordoma: Implications for T-cell function and viability**. Tianyi Wang. Brown University Health, Providence, RI, United States.

C126 **Lactobacillus-Derived Exosomes Target Ferroptosis and Cancer Stemness to Overcome Therapeutic Resistance in Head and Neck Cancer, with Preferential Efficacy in HPV-Positive Tumors**. Jae Won Chang. Department of Otolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Korea, Republic of.

C127 **Modulating the tumor niche-specific protein corona of nanomedicines for the precision targeting of chemoresistant cells using patient-derived organoids**. Meenu Priya Resmi. Cell and Molecular Medicine, College of Medicine, University of Arizona, Tucson, AZ, United States.

C128 **Disrupting the Oncobiosphere: CAF-Targeting Therapy with Penetrium™ Reverses Pseudo-Resistance in Tumors**. Sue Jang. HYUNDAI BIOSCIENCE CO., LTD., Seoul, Korea, Republic of.

C129 **Fostamatinib as a STAT3 inhibitor and potential therapeutic for triple negative breast cancer and high grade serous ovarian cancer**. Katherine Veronneau. University of New Hampshire, Durham, NH, United States.

C130 **Identifying a novel therapeutic target, DKK1, in ESR1 mutant breast cancers**. Kristen Young. Loyola University Chicago, Maywood, IL, United States.

C131 **Abaloparatide and Paclitaxel Combination Therapy Improves Bone Volume and Tumor Burden in Bone-Metastatic Breast Cancer**. Jade Miller. Vanderbilt University Medical Center, Nashville, TN, United States.

C132 **Screening of Molecular Glue Degraders Using the DIANTHUS Technology Platform**. Tiejun Bing. ICE Bioscience, Beijing, China.

C133 **Distinct aspects of β-catenin biology drive multiple biologically rational FOG-001 combinations for MSS colorectal cancer**. Brandon Nicolay. Parabilis Medicine, Cambridge, MA, United States.

C134 **Inhibition of KRAS-G12D as a radiosensitization strategy for KRAS-G12D-mutant pancreatic ductal adenocarcinoma cells**. Halil Corbali. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

C135 **CBL0137 as a promising therapeutic strategy for anaplastic, treatment-emergent neuroendocrine prostate cancer**. Sayuri Herath. Queensland University of Technology, Australia, Brisbane, QLD, Australia.